FDA Approves Clinical Trial for Abl Bio’s Dual-Antibody ADC Candidate
Abl Bio announced on March 3rd that the U.S. Food and Drug Administration has approved the Investigational New Drug application for its dual-antibody...
Search results for "new drug development"
VigenCell "Primary Endpoint Achieved"... Will a Domestic NK/T Lymphoma New Drug Be Born?
VigenCell has announced plans to apply for conditional approval within the year as it successfully completed commercialization clinical trials for...
Onconic’s ‘Nesuparib’ Secures U.S. FDA Orphan Drug Designation for Small Cell Lung Cancer
Onconic Therapeutics announced on the 24th that its novel anti-cancer candidate, 'Nesuparib', has been designated as an...
ABL Bio Publishes Review Paper on Dual Antibodies in International Journal
ABL Bio announced on the 11th that it published a review paper on the next-generation immune-oncology dual antibody...
LigaChemBio Receives Milestone from Czech Sotio Biotech
LigaChem Biosciences announced on the 9th that it will receive milestone payments based on successful product...
Eubiologics Reports Net Profit for Two Consecutive Years, What’s Next?
Cholera vaccine specialist Eubiologics has shown strong performance growth, recording net profits for two consecutive...
Dementia Injection Drug ‘Lecanemab’ Formulation and Dosage Diversification... Will It Compete with Oral Medications?
American Biogen and Japanese Eisai are moving quickly to change the formulation and dosage of the dementia treatment...
Generic Drug Price Reduction: How Much Benefit Will It Bring to Patients?
These days, the pharmaceutical industry is focused on the topic of 'drug price reduction.
Can We Break Through Chemotherapy Resistance? A New Target for Triple-Negative Breast Cancer Appears
Among breast cancers, ‘triple-negative breast cancer ’ is particularly challenging to treat.
Pharmaceutical Industry Establishes Successive R&BD Subsidiaries... Is Yuhan Corporation Joining?
Yuhan Corporation recently announced plans to establish a specialized subsidiary for 'Research and Business Development...